Dr Gabriela Gomez Guillen
Honorary Associate Professor
Economics of Infectious Diseases
Gabriela has over ten years of research experience in economic and impact evaluation of new technologies, most of it in infectious diseases such as HIV and TB. She works closely with policy and decision makers globally and in-country (Brazil, Peru, Tanzania, South Africa, Zambia, Zimbabwe, Nigeria, Kenya, India, Bangladesh, and China). Her research focuses on the inclusion of economic methods in infectious disease modelling to inform policy and better practice. She obtained her PhD at Imperial College London in Infectious Disease Epidemiology, on a porject looking at prevention and control of sexually transmitted diseases in sex worker populations in Peru. From 2011 to 2016, she led operational research projects evaluating prevention programs for key populations in sub-Saharan Africa. These programs include HIV prevention for truck drivers and sex workers in Zambia, Zimbabwe and South Africa; cardiovascular disease prevention in slums in Kenya and rural Nigeria; expansion of antiretroviral services (PrEP and immediate treatment) for female sex workers in South Africa, and ante-natal care interventions in rural Nigeria. In 2017, she joined the School and the Social and Mathematical Epidemiology Group. She is a member of the Global Health Cost Consortium (GHCC) and the TB modelling and analysis consortium (TB-MAC), leads the economic theme and serves on the steering committee of the Centre for the Mathematical Modelling of Infectious Diseases. Currently, she leads research on the inclusion of equity cosiderations in transmission modelling to inform priority setting.
I am currently a tutor and supervisor in the economic evaluation and proejct modules of the distance learning programme of the MSc Public Health.
My research interests include equity-informative analyses to inform priority setting using transmission models and economic evaluations of the scale-up of new technologies in HIV and TB, such as shortened/re-purposed regimens for first line and MDR treatment of TB. More broadly, the imporving standards and use of cost data in transmission models. I am a member of the TB Modelling and Analysis Consortium (TB MAC) and the Global Health Cost Consortium.